MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma
Indian Pharma Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 621.65 -0.72% | 620.85 -0.57% | More Info
|
|
| AJANTA PHARMA | 1,015.70 -0.83% | 1,015.00 -1.17% | More Info
|
|
| ALEMBIC PHARMA | 559.30 4.66% | 557.90 4.17% | More Info
|
|
| BIOCON | 607.75 -1.23% | 607.75 -1.21% | More Info
|
|
| CADILA HEALTHCARE | 330.65 -1.84% | 330.70 -1.72% | More Info
|
|
| CIPLA | 560.15 -0.33% | 561.10 -0.08% | More Info
|
|
| DIVIS LABORATORIES | 1,702.00 -1.36% | 1,701.50 -1.33% | More Info
|
|
| GLENMARK PHARMA | 625.65 -2.18% | 626.10 -2.04% | More Info
|
|
| INDOCO REMEDIES | 198.40 -0.20% | 199.15 0.05% | More Info
|
|
| IPCA LABS | 962.50 -0.67% | 963.75 -0.03% | More Info
|
|
| J.B.CHEMICALS | 342.25 -1.58% | 342.70 -1.32% | More Info
|
|
| LUPIN | 831.55 -0.31% | 831.65 -0.50% | More Info
|
|
| NATCO PHARMA | 532.40 -1.73% | 533.65 -1.00% | More Info
|
|
| NIFTY 50 | Not Listed | 11,594.45 -1.35% | More Info
|
|
| ORCHID PHARMA LTD | 5.50 -3.34% | 18.90 -2.83% | More Info
|
|
| PANACEA BIOTECH | 198.05 -1.81% | 199.60 -1.16% | More Info
|
|
| PIRAMAL ENTERPRISES | 2,554.85 -3.73% | 2,550.20 -3.76% | More Info
|
|
| S&P BSE SENSEX | 38,645.18 -1.26% | Not Listed | More Info
|
|
| STRIDES PHARMA SCIENCE | 476.20 -2.47% | 477.70 -2.04% | More Info
|
|
| SUN PHARMA | 454.50 -1.64% | 454.50 -1.88% | More Info
|
|
| TORRENT PHARMA | 1,814.05 -0.83% | 1,811.90 -1.34% | More Info
|
|
| WOCKHARDT | 424.35 -3.36% | 424.70 -3.29% | More Info
|
BSE prices: April 22, 2019 (Close) NSE prices: April 22, 2019 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 9,277.5 (down 1.4%). The index is down 10.0% over the last 30 days. And over the last 1 year, it has lost 1.2%.
Within the Indian Pharma sector, the top gainer was ALEMBIC PHARMA (up 4.7%). On the other hand, PIRAMAL ENTERPRISES (down 3.7%) and WOCKHARDT (down 3.4%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 11,594.5 (down 1.4%).
|
| |
Today's Market
Indian Indices Continue Downtrend; Sensex Ends 495 Points Lower(Closing)
Indian share markets witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.
Related Views on News
INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)
Mar 28, 2019 | Updated on Mar 28, 2019Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.
J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)
Mar 28, 2019 | Updated on Mar 28, 2019Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.
PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)
Apr 9, 2019It's a matter of time before the stocks catch the fancy of the markets and big investors.
3 Indian Stocks with Amazon-Like Potential(Profit Hunter)
Apr 10, 2019We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.
This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)
Apr 10, 2019How Dell got its mojo back.
This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)
Apr 12, 2019This critical business strategy has enabled companies to scale their operations faster.
Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)
Apr 12, 2019Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.
More|
| |
S&P BSE HEALTHCARE
Apr 22, 2019 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.